Business
Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week
Sobi® (STO: SOBI) today announced that data on Aspaveli/Empaveli in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) and NASP in uncontrolled gout will be presented at ASN Kidney Week 2025, 5-9 November in Houston, Texas. In total, the company will be present 1 oral and 6 poster presentations for Aspaveli/Empaveli, as well as 3 poster presentations for NASP.
About this update from Swedish Orphan Biovitrum Ab
[{"type":"text","content":"STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that data on Aspaveli/Empaveli in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) and NASP in uncontrolled gout will be presented at ASN Kidney Week 2025, 5-9 November in Houston, Texas. In total, the company will be present 1 oral and 6 poster presentations for Aspaveli/Empaveli, as well as 3 poster presentations for NASP.","length":453,"tagName":"p"},{"type":"text","content":"New one-year data reinforces the robust and sustained efficacy of Aspaveli/Empaveli (pegcetacoplan) in patients with C3G and primary IC-MPGN.","length":141,"tagName":"p"},{"type":"text","content":""Patients on Aspaveli/Empaveli maintained proteinuria reduction, irrespective of taking immunosuppressants and independent of their baseline proteinuria levels. One third of patients achieved complete proteinuria remission compared to 3% for placebo at week 26. These benefits were maintained through one year, and patients who switched from placebo experienced similar improvements. This demonstrates the potential of Aspaveli/Empaveli to transform care for people living with these rare diseases, who have a high risk of kidney failure," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi.","length":649,"tagName":"p"},{"type":"text","content":"Sobi will also present data showing NASP maintained stable renal function throughout the 6-month study period, with a higher proportion of patients experiencing improvement in CKD stage compared to placebo among those with uncontrolled gout and stage 3 chronic kidney disease. Additionally, NASP treatment led to a reduction in gout-related clinical manifestations and was generally well tolerated.","length":398,"tagName":"p"},{"type":"text","content":"Key data to be presented at ASN Kidney Week 2025","length":48,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.17em;VERTICAL-ALIGN:TOP;","val":[{"type":"text","content":" Aspaveli/Empaveli (pegcetacoplan) ","length":33,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.17em;VERTICAL-ALIGN:TOP;TEXT-ALIGN:RIGHT;","val":[{"type":"text","content":"","length":...